K
Katherine L. Williams
Researcher at University of California, Berkeley
Publications - 19
Citations - 2279
Katherine L. Williams is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Dengue virus & Epitope. The author has an hindex of 17, co-authored 19 publications receiving 2051 citations. Previous affiliations of Katherine L. Williams include Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
Martina Beltramello,Katherine L. Williams,Cameron P. Simmons,Annalisa Macagno,Luca Simonelli,Nguyen Than Ha Quyen,Soila Sukupolvi-Petty,Erika Navarro-Sanchez,Paul R. Young,Aravinda M. de Silva,Félix A. Rey,Luca Varani,Stephen S. Whitehead,Michael S. Diamond,Eva Harris,Antonio Lanzavecchia,Federica Sallusto +16 more
TL;DR: These findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue.
Journal ArticleDOI
Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification
Scott J. Balsitis,Katherine L. Williams,Ruben Lachica,Diana Flores,Jennifer L. Kyle,Erin Mehlhop,Syd Johnson,Michael S. Diamond,P. Robert Beatty,Eva Harris +9 more
TL;DR: It is shown that passive administration of anti-DV antibodies is sufficient to enhance DV infection and disease in mice using both mouse-adapted and clinical DV isolates, and a genetically engineered antibody variant that cannot bind FcγR exhibited prophylactic and therapeutic efficacy against ADE-induced lethal challenge.
Journal ArticleDOI
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.
Soila Sukupolvi-Petty,S. Kyle Austin,Michael Engle,James D. Brien,Kimberly A. Dowd,Katherine L. Williams,Syd Johnson,Rebeca Rico-Hesse,Eva Harris,Theodore C. Pierson,Daved H. Fremont,Michael S. Diamond +11 more
TL;DR: Overall, these studies define the structural and functional complexity of antibodies against DENV-2 with protective potential.
Journal ArticleDOI
Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.
Magelda Montoya,Lionel Gresh,Juan Carlos Mercado,Katherine L. Williams,Maria José Vargas,Gamaliel Gutierrez,Guillermina Kuan,Aubree Gordon,Angel Balmaseda,Eva Harris +9 more
TL;DR: Age, study year and time interval between consecutive DENV infections influence inapparent versus symptomatic infection outcome, while sex and infection number have no significant effect, and results suggest that the window of cross-protection induced by a first infection with DENV against a second symptomatic infections is approximately 2 years.
Journal ArticleDOI
Mouse STAT2 Restricts Early Dengue Virus Replication
Joseph Ashour,Juliet Morrison,Maudry Laurent-Rolle,Alan Belicha-Villanueva,Courtney R. Plumlee,Dabeiba Bernal-Rubio,Katherine L. Williams,Eva Harris,Ana Fernandez-Sesma,Christian Schindler,Adolfo García-Sastre +10 more
TL;DR: It is shown that differences in NS5 mediated binding and degradation between human and mouse STAT2 maps to a region within the STAT2 coiled-coil domain, and that overcoming this restriction through transgenic mouse technology may help in the development of a long-sought immune-competent mouse model of dengue virus infection.